Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Alternating Sunitinib and Bevacizumab in Advanced Renal Cell Carcinoma
NCT02919371Phase 2Unknown
- Sponsor
- King Faisal Specialist Hospital and Research Centre
- Start
- Dec 2014
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in clear cell renal cell carcinoma (ccRCC), sponsored by King Faisal Specialist Hospital and Research Centre. Primary endpoints: Maximum Tolerated Dose of Bevacizumab in combination with Sunitinib at 12 weeks, Objective Response Rate at 6 months and 1 more. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT02919371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02919371.